| ORIGINAL ARTICLE |
|
| Year : 2017 | Volume
: 5
| Issue : 4 | Page : 131-135 |
|
|
Serum ferritin as a guide for chelation therapy in patients of sickle cell anemia
Anjali Edbor1, Aboli Dahat2, Himanshu Dua1
1 Associate Professor, Department of Pediatrics, NKP Salve Institute of Medical Sciences & Lata Mnageshkar Hospital, Nagpur, India
2 Assistant Professor, Department of Pediatrics, NKP Salve Institute of Medical Sciences & Lata Mnageshkar Hospital, Nagpur, India
Correspondence Address:
Anjali Edbor
Associate Professor, Department of Pediatrics, NKP Salve Institute of Medical Sciences & Lata Mnageshkar Hospital, Nagpur
India
 Source of Support: None, Conflict of Interest: None
DOI: 10.4103/2321-7006.302555
|
|
|
Background: Now-a-days increasing numbers of patients with sickle cell disease (SCD) are receiving blood transfusions. As a result, these patients require treatment with either chelator drugs or exchange transfusion to prevent tissue injury from iron overload. In such cases, serum ferritin (SF) is a noninvasive measure widely used to monitor iron load.
Objective: To assess the iron load in patients of SCD by means of serum ferritin levels
Methodology: All the patients of SCD proven by Hb electrophoresis presenting to our hospital & consenting for study were evaluated in terms of history, CBC and reticulocyte count. Iron status was measured by means of measuring SF levels.
Results: We found that those patients who had severe anemia ( Hb < 5 gm/dl), required more transfusions and hence serum ferritin levels were highly elevated in severely anemic patients as compared with those who had mild anemia ( Hb> 7 gm/dl). The result was found statistically significant (p value - 0.000) in those who required total blood transfusion more than 100 ml/kg/yr.
Conclusion: There is increase risk of iron overload in patients of sickle cell anemia who receive chronic blood transfusions for prevention of various sickle cell crises.
|
|
|
|
| [PDF]* |
|
 |
|
